Atypical depression spectrum disorder - neurobiology and treatment.
Murck, Harald · Acta neuropsychiatrica · 2003 · DOI
Quick Summary
This article explores a type of depression with unusual symptoms—like eating more and sleeping more instead of less—that is often overlooked in standard depression assessments. The author suggests this pattern of depression shares biological similarities with chronic fatigue syndrome, fibromyalgia, and other related conditions, and that all of these may involve a common problem with how the body regulates stress hormones. Different medications may work better for this type of depression than those typically used for other forms.
Why It Matters
This work directly connects ME/CFS to depression and HPA axis dysfunction, providing a neurobiological framework for understanding why ME/CFS and atypical depression co-occur and why standard depression treatments may be ineffective. Recognition of ME/CFS as part of the 'atypical depression spectrum' could shift both diagnosis and treatment approaches, potentially leading to more appropriate pharmacological interventions for patients with ME/CFS who experience depression.
Observed Findings
Atypical depression with reversed vegetative signs (hyperphagia, hypersomnia) is underrepresented in standard depression rating scales like the HAMD
Somatoform disorders, neurasthenia/chronic fatigue syndrome, and fibromyalgia are epidemiologically and phenomenologically related to atypical depression
HPA axis suppression (rather than activation) appears common across the proposed atypical depression spectrum
MAO inhibitors, low-dose tricyclic antidepressants, and 5-HT3 antagonists have demonstrated therapeutic efficacy in atypical depression
Hypericum extracts show therapeutic potential for symptoms within the atypical depression spectrum
Inferred Conclusions
Atypical depression, chronic fatigue syndrome, fibromyalgia, and somatoform disorders form a biological spectrum united by decreased HPA axis activity
Conventional antidepressant treatments designed for melancholic depression may be inappropriate for the atypical depression spectrum
Pharmacological interventions targeting HPA suppression (rather than activation) may be more effective for this spectrum of disorders
Remaining Questions
What specific mechanisms explain HPA axis suppression across the atypical depression spectrum?
What This Study Does Not Prove
This editorial does not present new empirical data proving that ME/CFS, fibromyalgia, and atypical depression share an identical HPA dysregulation mechanism—it proposes a conceptual framework. It does not establish causality or demonstrate that the proposed treatment recommendations are superior to existing approaches through controlled trials. The author's claims about medication efficacy are based on disparate existing studies rather than a rigorous meta-analysis or new evidence.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →